MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Out-licensing

Diagnostic test for chronic obstructive pulmonary disease

Columbia Technology Ventures
Lead Inventor: Gerard M. Turino Problem or Unmet Need: One of the key measurements in Chronic Obstructive Pulmonary Disease (COPD) diagnosis is lung elastin degradation which occurs with the development of pulmonary emphysema. Current measurements of...

Full description

Lead Inventor: Gerard M. Turino Problem or Unmet Need: One of the key measurements in Chronic Obstructive Pulmonary Disease (COPD) diagnosis is lung elastin degradation which occurs with the development of pulmonary emphysema. Current measurements of elastin peptides are dependent on immunoassays, which have varied specificity with different antibodies. Therefore, there is a need for standardized methods of accurately detecting and measuring elastin components for the purpose of diagnosing and/or treating COPD, chronic bronchitis, emphysema, refractory asthma, and other related diseases. This technology provides a more sensitive and more accurate method to detect and quantify elastin components by mass spectrometry. By this technology, better diagnosis and treatment for COPD and other related diseases could be developed. Details of the Invention: This technology adapted mass spectrometry to detect and quantify desmosine and isodesmosine in body fluids or tissue, as a marker of determining the level of elastic fiber degradation in patients. Applications: • Method of diagnosing and treating elastin fiber injuries • Method of validating candidate compounds for use in treating COPD, chronic bronchitis, emphysema, refractory asthma, and other related diseases Advantages: • This technology provides more sensitive and more accurate method to quantify elastin components by mass spectrometry, compared with previous methods • The technology allows detection and quantification of different elastin components spontaneously Patent Status: International Patent Application (WO/2008/091633) Publications: Turino GM et al. Chest. 2007; 131(5): 1363-71 Licensing Status: Available for Licensing and Sponsored Research Support

Patent information

Pat. Title: Methods of Validating Candidate Compounds for Use in Treating COPD and Other Diseases Methods of Validating Candidate Compounds for Use in Treating COPD and Other Diseases

Publication #: WO/2008/091633

App. #: 60/881,949 PCT/US08/00871

Patent #: WO 08/091633

Type of business relationship sought

Licensing or sponsored research support

Licensing contact

Sara Gusik
Technology Licensing

Contact directly

Company details

Columbia Technology Ventures

Columbia Technology Ventures manages Columbia University’s intellectual property portfolio and serves as the University’s gateway for companies seeking novel technology solutions.

View profile

Related reports

Are you looking for reports related to this particular subject. Our Reports section is the best place to start.

Related items

Related categories

Clients in focus...

Get the Flash Player to see this rotator.

Partnering and licensing intelligence in life sciences industry
EthyPharm
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us